Tempest Therapeutics(TPST) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Tempest Reports First Quarter 2025 Financial Results and Provides Business Update Brisbane, CA, May 13, 2025 – Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2025 and provided a corporate update. "The amezalpat program continues to produce data that reinforce its potential as a cancer therapy, most recently in a ...